NCT07301437Not yet recruitingPhase 4
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
Source: ClinicalTrials.gov · Last updated 23 Mar 2026
Brief summary (registry, in English)
To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 11 Dec 2025
- Start date
- 1 May 2026
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Diseases
- Obesity
- NCT number
- NCT07301437
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 1 May 2026 to the primary completion date, 31 Aug 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy to liraglutide, orlistat or excipients
- Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
- Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers
- Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).
Lab values
- Severe liver and kidney dysfunction: ALT or AST\> three times the upper limit of normal, or eGFR \<30 mL/min
Other
- Pregnant or lactating women
Who the study is looking for
- BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
- Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
- No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.